Clinical trials: Nonsmall Cell Lung Cancer Stage III
Lung Neoplasms
Docetaxel in Non Small Cell Lung Cancer (NSCLC)
Primary objective: To classify the 2 study groups, according to the tumoral response. Secondary objectives: To evaluate the percentage of focused control per year. To calculate the time until progression.
- Trial name
- NCT00258739
- Testing
- Docetaxel + carboplatin + radiotherapy + docetaxel + gemcitabine, Docetaxel + gemcitabine + carboplatin + radiotherapy
- Where
- Spain
- Volunteers
- 140 people
- Sponsor
- Sanofi
Recurrent Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8
Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer
This phase III trial studies how well an antibody (durvalumab) with chemotherapy and radiation therapy (chemoradiation) works in treating patients with stage III non-small cell lung cancer that cannot be removed by surgery…
- Conditions
- Recurrent Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8
- Trial name
- NCT04092283
- Testing
- Carboplatin, Cisplatin, Durvalumab
- Where
- 830 sites in United States, Guam
- Volunteers
- 660 people
- Sponsor
- National Cancer Institute (NCI)
Stage III NSCLC
Clinical Trial for Evaluating Efficacy and Safety of PDR001 in Concurrent Plus Consolidation Versus Consolidation Only in Addition to Standard Chemoradiotherapy in Unresectable Stage III NSCLC Patients (PASTURE)
This is a multi-center, open-label, randomized Phase 2 trial evaluating PDR001 in two arms for concurrent chemoradiation and consolidation in the treatment-naïve patients with locally advanced, unresectable stage III NSCLC.
- Trial name
- NCT03945227
- Testing
- standard platinum-based concurrent chemoradiotherapy, followed by consolidation with PDR001, PDR001 concurrent with standard platinum-based chemoradiation, followed by consolidation with PDR001
- Where
- South Korea
- Sponsor
- Yonsei University
Lung Cancer
Erlotinib, Paclitaxel, and Carboplatin Combined With Radiation Therapy for Stage III Non-Small Cell Lung Cancer
RATIONALE: Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor…
- Trial name
- NCT00278148
- Testing
- carboplatin, Erlotinib, paclitaxel
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Nathan Pennell, MD, PhD
Lung Cancer
Chemotherapy Plus Radiation Therapy With or Without Surgery in Treating Patients With Stage IIIA Non-small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining radiation therapy with chemotherapy may kill more tumor cells.
- Trial name
- NCT00002550
- Testing
- cisplatin, etoposide, conventional surgery
- Where
- 16 sites in United States, South Africa
- Volunteers
- 429 people
- Sponsor
- Radiation Therapy Oncology Group
Exercise, Neoplasms
Monitoring and Telecoaching of Physical Activity in Patients With Stage III and IV Non-small Cell Lung Cancer
This study is a prospective non-randomised control study to evaluate the efficacy of a physical activity promotion program on the experience of physical activity in patients with stage III and IV non-small cell lung cancer…
- Trial name
- NCT03883243
- Testing
- Telecoaching
- Where
- Belgium
- Volunteers
- 32 people
- Sponsor
- KU Leuven
Non Small Cell Lung Cancer
DE-CT in Lung Cancer Proton Therapy
Dose distribution calculations for proton therapy are more accurate when based on DE-CT than on SE-CT. It is however unclear what the quantitative benefit of repeated DE-CT calculations is for lung cancer patients.
- Trial name
- DE-CT (NCT02844140)
- Testing
- DE-CT's and SE-CT
- Where
- Netherlands
- Sponsor
- Maastricht Radiation Oncology
Lung Cancer
Carboplatin, Irinotecan, and Radiation Therapy Followed By Docetaxel in Treating Patients With Newly Diagnosed Stage III Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy, such as carboplatin, irinotecan, and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00449020
- Testing
- Carboplatin, Docetaxel, irinotecan hydrochloride
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- University of Miami
Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Carcinoma
Recombinant Interleukin-15 in Treating Patients With Advanced Melanoma, Kidney Cancer, Non-small Cell Lung Cancer, or Squamous Cell Head and Neck Cancer
This phase I trial studies the side effects and best dose of recombinant interleukin-15 in treating patients with melanoma, kidney cancer, non-small cell lung cancer, or head and neck cancer that has spread to other places in the…
- Conditions
- Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Carcinoma, Recurrent Non-Small Cell Lung Carcinoma, Recurrent Renal Cell Carcinoma
- Trial name
- NCT01727076
- Testing
- Laboratory Biomarker Analysis, Pharmacological Study, Recombinant Human Interleukin-15
- Where
- 5 sites in United States
- Volunteers
- 20 people
- Sponsor
- National Cancer Institute (NCI)
Lung Cancer
Epidermal Growth Factor Receptor and K-ras Mutations in Patients With Stage III Non-Small Cell Lung Cancer
RATIONALE: Collecting and storing samples of tissue from patients with cancer to study in the laboratory may help doctors learn more about changes that may occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00898924
- Testing
- molecular diagnostic method, mutation analysis
- Volunteers
- 60 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Non-small Cell Lung Cancer Stage III
Pilot Study of a Novel Type of CT Scan to Assess Treatment Response During Chemoradiotherapy for Stage III Non-Small Cell Lung Cancer
Dual-energy CT (DECT) provides information on the blood volume in tumors and lymph nodes. As tumors respond to treatment, preliminary data suggests that the blood volumes changes as well.
- Trial name
- NCT02053285
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Rush University Medical Center
Non-Small Cell Lung Cancer
JoLT-Ca Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) for Lung Cancer
To Determine if SAbR improves survival over SR in High Risk Operable Stage I NSCLC
- Trial name
- STABLE-MATES (NCT02468024)
- Testing
- Lung Surgery, Radiation therapy
- Where
- 50 sites in United States, Australia and 2 more
- Volunteers
- 272 people
- Sponsor
- University of Texas Southwestern Medical Center
Carcinoma, Non-Small-Cell Lung
A Study to Evaluate PK, Efficacy, and Safety of BAT3306 Plus Chemo and Compare With Keytruda®(EU/US) in Participants With IV nqNSCLC
To compare the pairwise PK similarities between BAT3306, EU-Keytruda, and US-Keytruda, all administered with pemetrexed and carboplatin.
- Trial name
- NCT06280196
- Testing
- BAT3306, EU-Keytruda®, US-Keytruda®
- Where
- China
- Volunteers
- 162 people
- Sponsor
- Bio-Thera Solutions
Stage III, Non-small Cell Lung Cancer
Neoadjuvant Chemotherapy and Tilelizumab in Stage III（cTNM-IIIA.IIIB）Non-small-cell Lung Cancer
This is a prospective, one-arm, phase II study aimed at evaluating tislelizumab combined with platinum-containing dual-drug chemotherapy as a neoadjuvant treatment, supplemented with tislelizumab after surgery in patients with…
- Trial name
- NCT04865705
- Testing
- tislelizumab
- Where
- China
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- West China Hospital
Recurrent Non-small Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer
Erlotinib Hydrochloride With or Without Cixutumumab in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
This randomized phase I/II trial is studying the side effects and best dose of cixutumumab and to see how well erlotinib hydrochloride works when given together with or without cixutumumab in treating patients with stage III or…
- Conditions
- Recurrent Non-small Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
- Trial name
- NCT00778167
- Testing
- cixutumumab, erlotinib hydrochloride, laboratory biomarker analysis
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- National Cancer Institute (NCI)
AIDS-Related Non-Hodgkin Lymphoma, Clinical Stage III Cutaneous Melanoma AJCC v8
Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer
This phase I trial studies the side effects of pembrolizumab in treating patients with human immunodeficiency virus (HIV) and malignant neoplasms that have come back (relapsed), do not respond to treatment (refractory), or have…
- Conditions
- AIDS-Related Non-Hodgkin Lymphoma, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Hepatocellular Carcinoma
- Trial name
- NCT02595866
- Testing
- Antiretroviral Therapy, Biopsy, Biospecimen Collection
- Where
- 12 sites in United States
- Volunteers
- 58 people
- Sponsor
- National Cancer Institute (NCI)
Cancer
Irradiated Donor Lymphocyte Infusion in Treating Patients With Relapsed or Refractory Hematologic Cancer or Solid Tumor
RATIONALE: When irradiated lymphocytes from a donor are infused into the patient they may help the patient's immune system kill cancer cells.
- Trial name
- NCT00161187
- Testing
- therapeutic allogeneic lymphocytes
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- University of Medicine and Dentistry of New Jersey
Non-small Cell Lung Cancer
Radiotherapy for NSCLC to a Individualized MLD
Our group has shown in a modeling study that increasing the radiation dose to pre-specified normal tissue dose constrains could lead to increased TCP with the same NTCP.
- Trial name
- BRONC MLD (NCT00573040)
- Where
- Netherlands
- Volunteers
- 180 people
- Sponsor
- Maastricht Radiation Oncology
Brain and Central Nervous System Tumors, Breast Cancer
Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer
RATIONALE: Radiolabeled drugs such as yttrium Y 90 SMT 487 can locate tumor cells and deliver tumor-killing substances to them without harming normal cells.
- Conditions
- Brain and Central Nervous System Tumors, Breast Cancer, Gastrointestinal Carcinoid Tumor, Islet Cell Tumor
- Trial name
- NCT00006368
- Testing
- yttrium Y 90-edotreotide
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Novartis Pharmaceuticals
Esophageal Cancer, Lung Cancer
Decitabine in Treating Patients With Unresectable Lung or Esophageal Cancer or Malignant Mesothelioma of the Pleura
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of decitabine in treating patients who have unresectable…
- Conditions
- Esophageal Cancer, Lung Cancer, Malignant Mesothelioma, Metastatic Cancer
- Trial name
- NCT00019825
- Testing
- decitabine
- Where
- 2 sites in United States
- Sponsor
- National Cancer Institute (NCI)